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Background
CD20 is a cell surface marker expressed 
on mature B cells and most malignant 
B cells. It does not modulate rapidly, 
is not shed, and is highly expressed, 
leading to its use as a target for 
immunotherapy. In 1997, rituximab, 
a chimeric anti-CD20 monoclonal 
antibody (mAb), was approved for use 
in the treatment of cancer following 
its efﬁcacy (46% response rate) in 
a phase II trial involving 37 patients 
with relapsed low-grade non-Hodgkin 
lymphoma [1]. Since then, rituximab 
has been approved for the treatment 
of numerous other B cell malignancies 
and is now being actively investigated 
for use in the treatment of autoimmune 
disorders such as rheumatoid arthritis 
and systemic lupus erythematosus 
[2,3]. As a result, rituximab has been 
administered to more than a million 
patients worldwide, making it the 
most successful immunotherapeutic 
(commercially and clinically) used to 
date.
Importantly, much of the therapeutic 
efﬁcacy of rituximab is seen when 
it is used in combination with other 
drugs. In the treatment of non-
Hodgkin lymphoma, rituximab is 
routinely given in conjunction with 
chemotherapy, which greatly enhances 
the therapeutic outcome in terms of 
response rates, durations of remissions, 
and improvements in survival [1,4–6]. 
A similar synergy is observed between 
rituximab and cyclophosphamide or 
methotrexate [2,7,8] in the treatment 
of autoimmune conditions [3]. In 
part, these effective combinations 
are afforded by the distinct toxicity 
proﬁles of the different drugs and the 
relatively mild side effects observed 
with rituximab treatment. For these 
reasons rituximab is an ideal drug for 
investigating powerful combination 
therapies.
One group of drugs that could 
potentially be useful in combination 
with rituximab is the statins. Statins 
target 3-hydroxy-3-methylglutaryl-
coenzyme A reductase (HMG-CoAR), 
which is the rate-limiting enzyme of 
the mevalonate pathway required 
for the synthesis of isoprenoids 
such as cholesterol [9]. As such, 
the main clinical use of statins to 
date has been in the treatment of 
hypercholesterolemia. However, in 
addition to inhibiting cholesterol 
synthesis, statins also have cytotoxic 
effects on tumor cells [10–13]. These 
cytotoxic effects are likely achieved 
through one of two downstream 
effects of HMG-CoAR inhibition. First, 
by reducing isoprenoid synthesis, 
statins impair protein prenylation, a 
critical process for the correct cellular 
localization and signaling activity of 
numerous proteins such as Ras that 
may be important for tumor cell 
survival. Second, reducing cholesterol 
synthesis can interfere with the 
formation of cholesterol-rich lipid 
microdomains, or “rafts,” within the 
plasma membrane. These lipid rafts 
are thought to represent localized 
signaling platforms and may be 
particularly important in providing cell 
survival signals to tumor cells [14,15]. 
Moreover, as prenylated proteins 
commonly localize to lipid raft regions, 
statin treatment may therefore doubly 
compromise the biological activity 
of these proteins, providing potent 
cytostatic and cytotoxic effects. Clearly 
statins have an obvious anti-tumor 
potential, and it seems sensible to 
consider whether they provide a useful 
drug combination in conjunction with 
rituximab.
Statins Decrease the Efficacy of 
Anti-CD20 mAb by Preventing 
Their Binding
In a new study published in this issue 
of PLoS Medicine [16], Jakub Golab 
and colleagues address this very issue: 
namely, how do statins affect rituximab 
treatment? Perhaps surprisingly, they 
show that instead of enhancing the 
ability of rituximab to kill target cells, 
statins are inhibitory. 
Rituximab has three main effector 
mechanisms: Complement-dependent 
cytotoxicity and antibody-dependent 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS
Medicine:
Winiarska M, Bil J, Wilczek E, Wilczynski 
GM, Lekka M, et al. (2008) Statins impair 
antitumor effects of rituximab by 
inducing conformational changes of 
CD20. PLoS Med 5(3): e64. doi:10.1371/
journal.pmed.0050064
Jakub Golab and colleagues found that 
statins significantly decrease rituximab-
mediated complement-dependent 
cytotoxicity and antibody-dependent 
cellular cytotoxicity against B cell 
lymphoma cells.
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cellular cytotoxicity (CDC and ADCC, 
respectively) and direct cytotoxic 
signaling [7,17–22] (reviewed in [23]). 
Using a number of well-established 
in vitro assays, Golab and colleagues 
clearly show that statins impair the 
ability of rituximab to lyse lymphoma 
cell lines with the help of either 
complement (CDC) or, to a lesser 
degree, effector cells (ADCC), and that 
this impairment occurs because surface 
binding of CD20 is greatly reduced in 
these cells [16]. The researchers did 
not examine the ability of statins to 
inhibit direct cytotoxic signaling, but 
presumably this was also reduced due 
to diminished mAb binding. Therefore, 
at least two (and likely all) of the main 
effector mechanisms of rituximab 
were reduced by statin treatment. 
After establishing that the loss of 
CD20 binding was due to a change in 
conformation of surface CD20 after 
statin treatment, the authors then 
performed experiments to examine 
the effect of statins on CD20 in vivo. 
Although the effects here were more 
marginal, again the evidence suggests 
that statins reduce the binding of 
rituximab to its target.
Statins as a Contraindication for 
Rituximab Treatment?
Given the potential implications of 
these ﬁndings, the next steps are to 
conﬁrm them and then to establish 
the CD20 status of patients on long-
term statin treatment. Subsequently, it 
will be important to address whether 
equivalent effects on CD20 binding 
are observed in patients suffering from 
malignant or autoimmune disease to 
determine whether B cells in these 
conditions are more or less susceptible 
to the effects of cholesterol depletion 
through statin treatment. Previous in 
vitro experiments with methyl-beta-
cyclodextrin indicate that the effects 
of cholesterol depletion on CD20 
mAb binding are highly dependent 
upon both the mAb and cell type 
[24,25]. Presumably, data on the 
effects of statins on rituximab use are 
already available through retrospective 
analysis, as it is likely that among the 
million patients treated with rituximab 
a proportion were also receiving 
statins. To date, very few cases of co-
administration have been reported, but 
it is important to note that in at least 
one of these, long-term statin treatment 
did not appear to impair the normal 
therapeutic effect of rituximab [26]. 
These data, coupled with the limited 
effects seen in Figure 9 of Golab and 
colleagues’ study [16], suggest that the 
pronounced effects of statin treatment 
on anti-CD20 binding observed on 
lymphoma cell lines in vitro may not 
translate to equivalent effects in vivo. 
However, note that the CD20 binding 
shown in [16] was assessed after only a 
three day treatment with atorvastatin; 
potentially greater effects would 
be observed after more protracted 
treatment. The deﬁnitive answer to the 
question of whether statins substantially 
affect CD20 binding and function in 
vivo awaits clinical investigation.
Assuming long-term statin treatment 
does indeed substantially reduce CD20 
detection in vivo, two obvious changes 
to clinical management should be 
made. First, extensive use of statins for 
the treatment of hypercholesterolemia 
should be a contraindication for the 
use of CD20 as a diagnostic marker 
for mature B cells. Second, statins 
should be removed from the treatment 
of patients with either malignant or 
autoimmune disease who are required 
to undergo CD20-speciﬁc therapy.
Other Combinations?
Interestingly, Golab and colleagues 
reported (but did not show) that 
inhibitors of farnesyltransferase and 
geranylgeranyltransferase did not 
decrease CD20-mediated CDC [16], 
indicating that the effect of statins on 
anti-CD20 mAb binding is independent 
of their effects on impaired protein 
prenylation. As prenylation inhibition 
is a central component of the anti-
tumor effect of statins [10,13,27,28], it 
is possible that farnesyltransferase and 
geranylgeranyltransferase inhibitors 
such as tipifarnib may work well in 
combination with rituximab. To 
discover if this is the case, a sensible way 
forward would be to examine the direct 
cell-killing activity of these reagents in 
combination with rituximab. Whether 
this combination will also fall foul of 
unexpected complications remains to 
be seen. 
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